VALN - Valneva inks COVID-19 vaccine purchase deal with Bahrain

Valneva (NASDAQ:VALN) has signed an advance purchase agreement with the Kingdom of Bahrain for the supply of 1M doses of the its inactivated COVID-19 vaccine candidate VLA2001. Shares up 11.3% premarket at $53.40. This is the second purchase agreement VALN has secured for VLA2001 since reporting positive data for its Phase 3 clinical trial Cov-Compare. Valneva has initiated a rolling submission process with the Bahraini National Health Regulatory Authority. “Subject to regulatory review and approval, we plan to start deliveries in the first quarter of 2022,” said Franck Grimaud, Chief Business Officer of Valneva. Recently, EU regulator started rolling review of Valneva's COVID-19 vaccine.

For further details see:

Valneva inks COVID-19 vaccine purchase deal with Bahrain